Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25736
Title: Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study.
Austin Authors: Mooi, Jennifer K ;Chionh, Fiona;Savas, Peter;Da Gama Duarte, Jessica;Chong, Geoffrey ;Brown, Stephen;Wong, Rachel;Price, Timothy;Wann, Alysson ;Skrinos, Effie;Mariadason, John M ;Tebbutt, Niall C 
Affiliation: Olivia Newton-John Cancer Research Institute
Research, Peter MacCallum Cancer Centre
School of Cancer Medicine, Olivia Newton-John Cancer Research Institute
Medical Oncology, Ballarat Regional Integrated Cancer Centre
Medical Oncology & Eastern Health Clinical School, Eastern Health
Oncology, Queen Elizabeth Hospital
School of Medicine, University of Melbourne
Austin Health
Olivia Newton-John Cancer Wellness and Research Centre
Medical Oncology
Issue Date: 29-Jan-2021
metadata.dc.date: 2021-01-29
Publication information: Clinical Cancer Research 2021; online first: 29 January
Abstract: To assess the efficacy and safety of dual anti-angiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC). Open label Phase II study enrolled patients with unresectable mCRC with no prior systemic treatment. All patients received bevacizumab 7.5mg/kg 3-weekly and trebananib 15 mg/kg weekly. The primary endpoint was disease control (stable disease, partial (PR) or complete responses (CR)) at 6 months (DC6m). Secondary endpoints included toxicity, response rate (ORR), progression-free survival (PFS) and overall survival (OS). Exploratory biomarkers in plasma angiogenesis-related proteins, tumour gene expression and plasma antibodies to tumour antigens were examined. 45 patients were enrolled from four Australian sites. DC6m was 63% (95% CI: 47-77). ORR was 17% (95% CI: 7-32), comprising 7 PRs. Median duration of response was 20 months (range 10-48 months). Median PFS was 8.4 months and median OS 31.4 months. G1-2 peripheral oedema and joint-related symptoms were common. Overall incidence of G3-4 adverse events (AEs) of any type was 33% (n=15). Expected AEs of bevacizumab treatment did not appear to be increased by the addition of trebananib. In a first-line mCRC population, the dual anti-angiogenic combination, bevacizumab plus trebananib, was efficacious with durable responses. The toxicity profile of the combination was manageable and did not exceed that expected with bevacizumab +/-chemotherapy. Exploratory biomarker results suggest that in addition to its anti-angiogenic activity, this combination may provide clinical benefit by enabling anti-tumour immunomodulatory effects, supporting ongoing trials of anti-angiogenic therapy combined with cancer immunotherapy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25736
DOI: 10.1158/1078-0432.CCR-20-2714
ORCID: 0000-0002-9392-5816
0000-0001-5999-428X
0000-0003-4289-5204
0000-0002-4926-5689
0000-0001-9536-316X
PubMed URL: 33514526
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Jun 19, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.